Therapeutics News and Research

RSS

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

5 Mar 2012

Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement

Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.

5 Mar 2012

Rigosertib drug shows promise against advanced pancreatic cancer

The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.

3 Mar 2012

Early surgical intervention stops seizures and improves quality of life

While the thought of any type of surgery can be disconcerting, the thought of brain surgery can be downright frightening. But for people with a particular form of epilepsy, surgical intervention can literally be life-restoring.

3 Mar 2012

Critical new details about structure of enterovirus 71

Researchers have discovered critical new details about the structure of a virus that causes potentially fatal brain swelling and paralysis in children, pointing toward designs for antiviral drugs to treat the disease.

3 Mar 2012

Scientists determine chemical features of DHPS enzyme's active site

More than 70 years after the first sulfa drugs helped to revolutionize medical care and save millions of lives, St. Jude Children's Research Hospital scientists have determined at an atomic level the mechanism these medications use to kill bacteria. The discovery provides the basis for a new generation of antibiotics that would likely be harder for bacteria to resist and cause fewer side effects.

2 Mar 2012

KF's TBI research director to speak at Washington conference

Jordan Grafman, PhD, director of Traumatic Brain Injury Research at Kessler Foundation, is an invited speaker at The 2nd Annual Traumatic Brain Injury Conference on March 6, 2012, in Washington, DC. Dr. Grafman will describe the long-term cognitive and social consequences of traumatic brain injury.

1 Mar 2012

Scripps Florida study to focus on four new classes of pain-relieving compounds

Scripps Florida scientists have been awarded $3.1 million by the National Institute on Drug Abuse, part of the National Institutes of Health, to study and develop several new compounds that could prove to be effective in controlling pain without the unwanted side effects common with opiate drugs, such as morphine, Oxycontin, and Vicoden.

1 Mar 2012

LAU-0901 drug protects brain in an experimental stroke model

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, has found that a synthetic molecule protected the brain in a model of experimental stroke.

29 Feb 2012

Study identifies how chemo drug combination kills pancreatic cancer cells

Cancer Research UK scientists have discovered how a combination of two chemotherapy drugs - already showing promise in clinical trials - destroys pancreatic cancer cells, according to research published in Cancer Discovery.

29 Feb 2012

KCC's geriatric oncology symposium to take place on March 9

Approaches to treating elderly cancer patients are evolving as more of the population ages and the need for specialized care becomes more evident. To address these issues and others, national thought leaders in geriatric oncology will gather at a unique symposium at the Kimmel Cancer Center at Jefferson (KCC) in Philadelphia on Friday, March 9, 2012, where they will present an overview of the latest advances in the understanding and treatment of cancer in older adults in an effort to impact patient care.

29 Feb 2012

FDA accepts Tau Therapeutics' mibefradil IND for treatment of cancer

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).

28 Feb 2012

UT Southwestern's chairman of pharmacology wins 2012 Rolf Luft Award

Dr. David Mangelsdorf, chairman of pharmacology at UT Southwestern Medical Center, has been awarded the 2012 Rolf Luft Award for research that has advanced understanding of nuclear receptor pathways.

28 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

Aesculap, Osseon partner to distribute VCF treatment devices

Osseon Therapeutics, Inc. announced today that the company has entered into an International Distribution Agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex SB (steerable balloon) in select regions of Europe and Asia.

From B. Braun Melsungen AG 27 Feb 2012

GSK, Angiochem to develop and commercialize LSD treatments

Angiochem announced today a global collaboration with GlaxoSmithKline (GSK) to discover, develop and commercialize treatments for lysosomal storage diseases.

27 Feb 2012

Celldex announces pricing of underwritten public offering of common stock

Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.

24 Feb 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

Scientists design compounds that act against myotonic dystrophy type 1 RNA

While RNA is an appealing drug target, small molecules that can actually affect its function have rarely been found. But now scientists from the Florida campus of The Scripps Research Institute have for the first time designed a series of small molecules that act against an RNA defect directly responsible for the most common form of adult-onset muscular dystrophy.

23 Feb 2012

Osseon's new vertebral augmentation device receives European CE Mark approval

Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.

22 Feb 2012